PMID- 38028143
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240130
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 15
DP  - 2023
TI  - CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a 
      patient with metastatic triple negative breast cancer: a case study.
PG  - 17588359231210675
LID - 10.1177/17588359231210675 [doi]
LID - 17588359231210675
AB  - Prognosis of metastatic triple negative breast cancer (mTNBC) remains poor 
      despite recent advances in therapeutic options. Trastuzumab deruxtecan (T-DXd) 
      has shown promising efficacy in patients with human epidermal growth factor 
      receptor 2 (HER2)-low breast cancer, which is defined by immunohistochemistry 
      (IHC) 1+ or 2+ and lack of HER2 amplification by fluorescence in situ 
      hybridization (FISH) testing. The purpose of the study is to evaluate the safety 
      and initial evidence of efficacy of intratumoral administration of 
      CF33-hNIS-anti-PD-L1 (CHECKvacc) against mTNBC. Oncolytic virus CHECKvacc 
      intratumoral injection is currently undergoing investigation in patients with 
      mTNBC as a single agent (NCT05081492). The patient was enrolled on the clinical 
      trial CHECKvacc for the Treatment of Metastatic Triple Negative Breast Cancer, 
      received a single dose of CHECKvacc, and discontinued the study due to lack of 
      immediate response. We report a case of a patient with mTNBC who was heavily 
      pretreated and presented with extensive dermal metastasis. Two dermal metastasis 
      biopsies in 2021 showed HER2 0 by IHC. The patient received a single dose of 
      CHECKvacc and discontinued the study due to lack of immediate response. 
      Twenty-five days later, the patient received treatment with T-DXd, and her tumor 
      regressed significantly. The patient's disease-free survival was 10 months 
      (December 2021-October 2022). The sequential treatment with intratumoral 
      injection of CHECKvacc followed by T-DXd may have significant clinical activity 
      in select patients with heavily pretreated mTNBC. ClinicalTrials.gov NCT05081492.
CI  - (c) The Author(s), 2023.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - Cedars-Sinai Medical Center, 127 S San Vicente Blvd, Los Angeles, CA 90048, USA.
FAU - Egelston, Colt
AU  - Egelston C
AD  - Department of Immune-Oncology, City of Hope Comprehensive Cancer Center and 
      Beckman Research Institute, Duarte, CA, USA.
FAU - Colunga Flores, Oscar
AU  - Colunga Flores O
AD  - Department of Immune-Oncology, City of Hope Comprehensive Cancer Center and 
      Beckman Research Institute, Duarte, CA, USA.
FAU - Chaurasiya, Shyambabu
AU  - Chaurasiya S
AD  - Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
FAU - Lin, David
AU  - Lin D
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Chang, Helen
AU  - Chang H
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Chong, Leslie Mi Ok
AU  - Chong LMO
AD  - Imugene Limited, Sydney, NSW, Australia.
FAU - Seiz, Amanda
AU  - Seiz A
AD  - Imugene Limited, Sydney, NSW, Australia.
FAU - Shah, Monil
AU  - Shah M
AD  - Imugene Limited, Sydney, NSW, Australia.
FAU - Meisen, W Hans
AU  - Meisen WH
AD  - Department of Translational Development, City of Hope Comprehensive Cancer 
      Center, Duarte, CA, USA.
FAU - Tang, Aileen
AU  - Tang A
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Martinez, Norma
AU  - Martinez N
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Pickett, Wichanee
AU  - Pickett W
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Murga, Mireya
AU  - Murga M
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Yost, Susan E
AU  - Yost SE
AUID- ORCID: 0000-0002-9422-0316
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Stewart, Daphne
AU  - Stewart D
AD  - Department of Medical Oncology and Therapeutics Research, City of Hope 
      Comprehensive Cancer Center, Duarte, CA, USA.
FAU - Zhang, Jianying
AU  - Zhang J
AD  - Department of Statistics, City of Hope Comprehensive Cancer Center, Duarte, CA, 
      USA.
FAU - Ede, Nicholas
AU  - Ede N
AD  - Imugene Limited, Sydney, NSW, Australia.
FAU - Modi, Badri
AU  - Modi B
AD  - Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
FAU - Kessler, Jonathan
AU  - Kessler J
AD  - Department of Radiology, City of Hope Comprehensive Cancer Center, Duarte, CA, 
      USA.
FAU - Rand, Jamie
AU  - Rand J
AD  - Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
FAU - Fong, Yuman
AU  - Fong Y
AUID- ORCID: 0000-0002-8934-9959
AD  - Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT05081492
GR  - P30 CA033572/CA/NCI NIH HHS/United States
PT  - Case Reports
DEP - 20231110
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC10640805
OTO - NOTNLM
OT  - CF33-hNIS-anti-PD-L1
OT  - CHECKvacc
OT  - T-DXd
OT  - triple negative breast cancer
COIS- YY has contracted research sponsored by Merck, Genentech, and Pfizer; is a 
      consultant for Pfizer, and Immunomedics; and is on the Speakers Bureau for 
      Genentech, AstraZeneca, Daiichi Sankyo, Pfizer, Merck, and Gilead. YF is 
      co-founder and has equity interest in XDemics Corporation; is a consultant for 
      Covidien; is on the advisory board and has common stock options for Theromics, 
      Vergent Biosciences, and Eureka Biologics; is on the advisory board and receives 
      compensation from Imugene; is a consultant and receives compensation from Iovance 
      Biotherapeutics; and is on the Data Safety Board for Sangamo Therapeutics and the 
      University of Alabama, Birmingham. The other authors declare that they have no 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/29 18:41
MHDA- 2023/11/29 18:42
PMCR- 2023/11/10
CRDT- 2023/11/29 17:10
PHST- 2023/06/05 00:00 [received]
PHST- 2023/10/12 00:00 [accepted]
PHST- 2023/11/29 18:42 [medline]
PHST- 2023/11/29 18:41 [pubmed]
PHST- 2023/11/29 17:10 [entrez]
PHST- 2023/11/10 00:00 [pmc-release]
AID - 10.1177_17588359231210675 [pii]
AID - 10.1177/17588359231210675 [doi]
PST - epublish
SO  - Ther Adv Med Oncol. 2023 Nov 10;15:17588359231210675. doi: 
      10.1177/17588359231210675. eCollection 2023.